Comparative Pharmacology
Head-to-head clinical analysis: ABACAVIR DOLUTEGRAVIR AND LAMIVUDINE versus ABACAVIR DOLUTEGRAVIR LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABACAVIR DOLUTEGRAVIR AND LAMIVUDINE versus ABACAVIR DOLUTEGRAVIR LAMIVUDINE.
ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE vs ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Abacavir is a guanosine analogue reverse transcriptase inhibitor that is phosphorylated to carbovir triphosphate, which competitively inhibits HIV reverse transcriptase and causes DNA chain termination. Dolutegravir is an integrase strand transfer inhibitor that blocks the strand transfer step of HIV DNA integration into the host genome. Lamivudine is a cytidine analogue reverse transcriptase inhibitor that is phosphorylated to lamivudine triphosphate, which competitively inhibits HIV reverse transcriptase and causes DNA chain termination.
Abacavir is a carbocyclic synthetic nucleoside analog guanosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase. Dolutegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks viral integration into host DNA. Lamivudine is a synthetic nucleoside analog cytosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase.
One tablet (600 mg abacavir / 50 mg dolutegravir / 300 mg lamivudine) taken orally once daily.
One tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) orally once daily.
None Documented
None Documented
Abacavir: 1.5-2 h. Dolutegravir: 14 h (range 11-18 h) supporting once-daily dosing. Lamivudine: 13-19 h (intracellular triphosphate t1/2 16-19 h in cells).
Abacavir: 1.5 hr (terminal half-life ~1.5 hr, but intracellular carbovir-TP half-life ~12-20 hr supports once-daily dosing). Dolutegravir: ~14 hr (terminal half-life, clinical context: once-daily dosing due to long intracellular half-life and high potency). Lamivudine: 5-7 hr (terminal half-life, intracellular half-life of lamivudine-TP ~18-22 hr supports once-daily dosing).
Abacavir: 83% renal (metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Dolutegravir: <1% renal, 64% fecal (as unchanged drug), 35% urinary (metabolites, mainly glucuronide). Lamivudine: 70% renal (unchanged via tubular secretion and glomerular filtration), 5-10% fecal.
Abacavir: 83% renal (primarily as metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Dolutegravir: 64% fecal (unchanged), 32% renal (minor as metabolites via UGT1A1 and CYP3A4). Lamivudine: >70% renal (unchanged via organic cation transport).
Category A/B
Category A/B
NRTI
NRTI